Anixa Biosciences (ANIX) Price & Analysis

Compare

506 Followers

ANIX Stock Chart & Stats

$3.16

-$0.08(-3.60%)

At close: Jan 08 4:00 PM EST

$3.16

-$0.08(-3.60%)

Day’s Range― - ―

52-Week Range$2.33 - $5.46

Previous CloseN/A

Volume56.82K

Average Volume (3M)204.54K

Market Cap

$99.14M

Enterprise Value$93.76M

Total Cash (Recent Filing)$15.17M

Total Debt (Recent Filing)$204.00K

Price to Earnings (P/E)―

Beta0.49

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding33,379,505

10 Day Avg. Volume193,788

30 Day Avg. Volume204,545

Financial Highlights & Ratios

PEG Ratio0.96

Price to Book (P/B)8.84

Price to Sales (P/S)0.00

P/FCF Ratio-18.69

Enterprise Value/Market Cap0.95

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-10.42K

Enterprise Value/Ebitda-8.01

Forecast

1Y Price Target

$7.00

Price Target Upside121.52% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentAnixa announced it executed a Data Transfer agreement with Cleveland Clinic, enabling transfer of P1 breast cancer vaccine study data, a key step toward assuming full IND sponsorship.

Financial StabilityWith $17.3M in cash, and a low burn rate, Anixa should have runway into FY27 and through key events generated by its partnerships to unlock investor value.

Strategic PartnershipsAnixa's strategic partnerships with leading cancer centers like Cleveland Clinic and Moffitt Cancer Center both validate its programs and ensures efficient capital use while the programs work toward generating clinical proof of concept which should pave the way to later-stage studies.

Bears Say

Anixa Biosciences News

Anixa provides update on Phase 1 ovarian cancer CAR-T clinical trial

Anixa Biosciences (ANIX) provided an update on patient outcomes observed in its ongoing Phase 1 ovarian cancer CAR-T...

4d ago

ANIX

Anixa Biosciences receives USAN Council approval for novel CAR-T therapy name

Anixa Biosciences (ANIX) announced that the U.S. Adopted Names, or USAN, Council approved “liraltagene autoleucel” for the non-proprietary...

11d ago

ANIX

Anixa Biosciences granted patent for breast cancer vaccine technology in Mexico

Anixa Biosciences (ANIX) announced that the Mexican Institute of Industrial Property – the IMPI – has issued a...

17d ago

ANIX

Anixa Advances Ovarian Cancer CAR-T With Higher Dosing

An announcement from Anixa Biosciences ( ($ANIX) ) is now available. On February 9, 2026, Anixa Biosciences reported...

4d ago

ANIX

Anixa announces transfer of IND for breast cancer vaccine from Cleveland Clinic

Anixa Biosciences (ANIX) announced that it has completed the transfer of the Investigational New Drug application, IND, for...

2M ago

ANIX

Anixa Biosciences Reports Positive Phase 1 Trial Results

Anixa Biosciences ( ($ANIX) ) just unveiled an announcement. On December 11, 2025, Anixa Biosciences announced positive final...

2M ago

ANIX

Anixa Biosciences says all primary endpoints met in breast cancer vaccine trial

Anixa Biosciences (ANIX) announced the presentation of final data from the Phase 1 clinical trial of its investigational...

2M ago

ANIX

Anixa Biosciences’ CAR-T therapy granted WHO approval of non-proprietary name

Anixa Biosciences (ANIX) announced that the International Nonproprietary Names, or INN, Expert Committee of the World Health Organization,...

3M ago

ANIX

Anixa Biosciences awarded patent covering breast cancer vaccine technology

Anixa Biosciences (ANIX) announced that the United States Patent and Trademark Office will issue U.S. Patent Number 12,472,205...

3M ago

ANIX

Anixa Biosciences executes data transfer with Cleveland Clinic

Anixa Biosciences (ANIX) announced that it has executed a data transfer agreement, or DTA, with Cleveland Clinic, as...

3M ago

ANIX

Anixa awarded patent in China covering breast cancer vaccine technology

Anixa Biosciences (ANIX) announced that the Chinese National Intellectual Property Administration, or CNIPA, has issued Patent Number ZL2020800215666,...

4M ago

ANIX

Anixa Biosciences completes patient visit in breast cancer vaccine trial

Anixa Biosciences (ANIX) announced the completion of the final patient visit in its breast cancer vaccine clinical trial....

4M ago

ANIX

Anixa Biosciences: Promising Clinical Progress and Financial Stability Underpin Buy Rating

Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Anixa Biosciences, retaining the price target of...

5M ago

ANIX

Promising Advancements and Strategic Positioning Propel Anixa Biosciences to a Buy Rating

Anixa Biosciences, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from...

5M ago

ANIX

ANIX FAQ

What was Anixa Biosciences’s price range in the past 12 months?

Anixa Biosciences lowest stock price was $2.33 and its highest was $5.46 in the past 12 months.

What is Anixa Biosciences’s market cap?

Anixa Biosciences’s market cap is $99.14M.

When is Anixa Biosciences’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Anixa Biosciences’s earnings last quarter?

Currently, no data Available

Is Anixa Biosciences overvalued?

According to Wall Street analysts Anixa Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Anixa Biosciences pay dividends?

Anixa Biosciences does not currently pay dividends.

What is Anixa Biosciences’s EPS estimate?

Anixa Biosciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Anixa Biosciences have?

Anixa Biosciences has 33,379,505 shares outstanding.

What happened to Anixa Biosciences’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Anixa Biosciences?

Currently, no hedge funds are holding shares in ANIX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Anixa Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-62.16%

Trailing 12-Months

Asset Growth

-25.52%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Anixa Biosciences

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Anixa Biosciences (ANIX) Earnings & Revenues

Historic Earnings Reports

ANIX Stock 12 Month Forecast

Average Price Target

$7.00

▲(121.52% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","8":"$8","2.75":"$2.75","4.5":"$4.5","6.25":"$6.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2.75,4.5,6.25,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Aug<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.94,3.252307692307692,3.5646153846153847,3.876923076923077,4.189230769230769,4.501538461538462,4.813846153846153,5.126153846153846,5.438461538461539,5.750769230769231,6.063076923076924,6.375384615384616,6.687692307692307,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.94,3.252307692307692,3.5646153846153847,3.876923076923077,4.189230769230769,4.501538461538462,4.813846153846153,5.126153846153846,5.438461538461539,5.750769230769231,6.063076923076924,6.375384615384616,6.687692307692307,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.94,3.252307692307692,3.5646153846153847,3.876923076923077,4.189230769230769,4.501538461538462,4.813846153846153,5.126153846153846,5.438461538461539,5.750769230769231,6.063076923076924,6.375384615384616,6.687692307692307,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.39,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.66,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.14,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.89,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.23,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.01,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.09,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.13,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.94,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >